Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Eitemau Tebyg

• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
  gan: Milojkovic, Dragana, et al.
  Cyhoeddwyd: (2012)
• European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
  gan: Marin, David, et al.
  Cyhoeddwyd: (2008)
• Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
  gan: Milojkovic, Dragana, et al.
  Cyhoeddwyd: (2010)
• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
  gan: Ibrahim, Amr R., et al.
  Cyhoeddwyd: (2011)
• Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
  gan: Marin, David, et al.
  Cyhoeddwyd: (2010)